Novasep appoints two key executives

Stephen Stefano heads up Novasep North American business and Patrick Glaser leads Novasep Synthesis division

05-May-2010 - France

Novasep announced the appointments of two highly experienced managers in its drive to grow the group’s US presence and develop its Novasep Synthesis division. Stephen F. Stefano becomes President and CEO of Novasep North American business, and Patrick A. Glaser President and CEO of the Novasep Synthesis division, a new position created as a result of its ongoing global integration. Stefano and Glaser also join Groupe Novasep’s executive management committee.

Before joining Novasep, Stefano was Senior Vice President at GlaxoSmithKline Pharmaceuticals in charge of Business Development for North America and New Product Planning. Stefano’s career spanned 29 years from 1981-2010 at Glaxo, GlaxoWellcome and GlaxoSmithKline, where he directed the sales of most business segments including Primary Care, Specialty, Hospital, and Managed Healthcare. He had full P&L responsibility for several multi-billion dollar divisions.

Glaser held senior management, strategic marketing and strategic business development positions successively at Knoll Pharmaceuticals (1986-1998), BASF Corporation (1998-2005) and Dr Reddy’s Laboratories (2005-2009), where he was Vice President of its active pharmaceutical ingredient business, and recently in charge of a strategic contract manufacturing acquisition and integration. Born in Austria, Patrick has spent 25 years in the USA, and masters both European and US business environments.

Novasep expects both to play an important role in its development plans over the next few years. The US will be a major source of growth for both Novasep Process and Novasep Synthesis divisions, while the group’s activity in synthetic molecule manufacture will remain globally its largest source of revenues.

These appointments follow last year’s hiring of Antoine Baule as president of the Novasep Process division, and the subsequent acquisition of the biopharmaceutical CMO Henogen, key milestones in the group’s strong expansion in biopharmaceutical manufacturing.

Other news from the department people

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics